repros

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept …

Major updates in the biotech sector over the past four trading days were on the pipeline and regulatory front from companies like Alkermes (ALKS – Analyst Report) and Amgen (AMGN – Analyst Report) among others.Recap of the Week’s Most Important Stories1. Alkermes’ experimental schizophrenia treatment, ALKS 3831, fared well in a mid-stage study. Earlier this year, the company had said […]